InSyGen Therapeutics Ltd joins the IIB

Founded in 2008 by Mr Stephen Wallace and Professor Russell Snell, InSyGen Therapeutics Ltd is using comparative genomics to discover novel human drug targets and develop therapeutics with an initial focus on obesity and diabetes. Co-location in the IIB provides the company with access to a broad range of relevant technology and expertise.